gallic acid has been researched along with Ovarian Neoplasms in 9 studies
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ovarian cancer is one of the leading causes of cancer-related mortality in women, and is often associated with drug resistance." | 1.72 | Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines. ( Abdullah, N; Ahmed, I; Al Bahlani, S; Al Balushi, N; Al Dhahli, B; Burney, IA; Dobretsov, S; Hassan, SI; Tamimi, Y; Tsang, BK, 2022) |
| "CP therapy is related to female ovarian cancer and causes female infertility." | 1.62 | Chemoprotective Effect of Syringic Acid on Cyclophosphamide Induced Ovarian Damage via Inflammatory Pathway. ( Chen, L; Li, Y; Liang, Y; Liu, J; Wang, W; Zhao, S, 2021) |
| "Ovarian cancer is the leading cause of mortality among malignant gynecological tumors." | 1.56 | Effect of Gallic acid and Myricetin on ovarian cancer models: a possible alternative antitumoral treatment. ( Castellanos-Mijangos, RD; Chávez-Munguía, B; González-Horta, C; Hernández-Ramírez, VI; Sánchez-Ramírez, B; Talamás-Rohana, P; Varela-Rodríguez, H; Varela-Rodríguez, L, 2020) |
| "To address this, SKOV3 and OVCAR3 ovarian cancer(OC) cell lines with clear cell and serous histology, two main OC subtypes, were exposed to FASN-inhibitor G28UCM." | 1.56 | Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. ( Colomer, R; Gerner, C; Grunt, TW; López-Rodríguez, ML; Semkova, M; Slany, A; Stübiger, G; Wagner, R; Wuczkowski, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Al Balushi, N | 1 |
| Hassan, SI | 1 |
| Abdullah, N | 1 |
| Al Dhahli, B | 1 |
| Al Bahlani, S | 1 |
| Ahmed, I | 1 |
| Tsang, BK | 1 |
| Dobretsov, S | 1 |
| Tamimi, Y | 1 |
| Burney, IA | 1 |
| Varela-Rodríguez, L | 1 |
| Sánchez-Ramírez, B | 1 |
| Hernández-Ramírez, VI | 1 |
| Varela-Rodríguez, H | 1 |
| Castellanos-Mijangos, RD | 1 |
| González-Horta, C | 1 |
| Chávez-Munguía, B | 1 |
| Talamás-Rohana, P | 1 |
| Grunt, TW | 1 |
| Slany, A | 1 |
| Semkova, M | 1 |
| Colomer, R | 1 |
| López-Rodríguez, ML | 1 |
| Wuczkowski, M | 1 |
| Wagner, R | 1 |
| Gerner, C | 1 |
| Stübiger, G | 1 |
| Sicard, AA | 1 |
| Suarez, NG | 1 |
| Cappadocia, L | 1 |
| Annabi, B | 1 |
| Yang, L | 1 |
| Qu, C | 1 |
| Jin, J | 1 |
| Yang, H | 1 |
| Pei, L | 1 |
| Liu, J | 1 |
| Wang, W | 1 |
| Chen, L | 1 |
| Li, Y | 1 |
| Zhao, S | 1 |
| Liang, Y | 1 |
| Pan, H | 1 |
| Wang, F | 1 |
| Rankin, GO | 2 |
| Rojanasakul, Y | 2 |
| Tu, Y | 1 |
| Chen, YC | 2 |
| Sánchez-Carranza, JN | 1 |
| Díaz, JF | 1 |
| Redondo-Horcajo, M | 1 |
| Barasoain, I | 1 |
| Alvarez, L | 1 |
| Lastres, P | 1 |
| Romero-Estrada, A | 1 |
| Aller, P | 1 |
| González-Maya, L | 1 |
| He, Z | 1 |
| Chen, AY | 1 |
9 other studies available for gallic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug R | 2022 |
Effect of Gallic acid and Myricetin on ovarian cancer models: a possible alternative antitumoral treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Flavonoids; Gallic Acid; Humans; Mice; Ova | 2020 |
Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.
Topics: Cell Line, Tumor; Cell Membrane; Cell Proliferation; Drug Resistance, Neoplasm; Fatty Acid Synthase, | 2020 |
Functional targeting of the TGF-βR1 kinase domain and downstream signaling: A role for the galloyl moiety of green tea-derived catechins in ES-2 ovarian clear cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Catechin; Cell Line, Tumor; Cell Movement; Female; Gallic Acid; H | 2021 |
Syringic acid regulates suppression of the STAT3/JNK/AKT pathway via inhibition of human ovarian teratoma cancer cell (PA-1) growth-in vitro study.
Topics: Cell Line, Tumor; Cell Proliferation; Female; Gallic Acid; Humans; MAP Kinase Kinase 4; Ovarian Neop | 2021 |
Chemoprotective Effect of Syringic Acid on Cyclophosphamide Induced Ovarian Damage via Inflammatory Pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antioxidants; Chemopr | 2021 |
Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
Topics: Apoptosis; Biflavonoids; Catechin; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Damage; Drug | 2017 |
Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
Topics: Acetylcysteine; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Dr | 2018 |
Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Female; Gallic Acid; Gene Expression Regulation, Neoplast | 2016 |